Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C8H10N6.5H2O.2H2O4S |
| Molecular Weight | 666.644 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.O.OS(O)(=O)=O.OS(O)(=O)=O.NNC1=C2C=CC=CC2=C(NN)N=N1.NNC3=C4C=CC=CC4=C(NN)N=N3
InChI
InChIKey=JOPVPUGEMVRMOY-UHFFFAOYSA-N
InChI=1S/2C8H10N6.2H2O4S.5H2O/c2*9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;2*1-5(2,3)4;;;;;/h2*1-4H,9-10H2,(H,11,13)(H,12,14);2*(H2,1,2,3,4);5*1H2
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of acute hypotension and hypertension on serum TSH concentrations in male rats. | 1979 Oct |
|
| [Rare liver damage caused by an antihypertensive and anti-arrhythmic agents]. | 1980 Apr 1 |
|
| Side-effects with long-term labetalol: an open study of 251 patients in a single centre. | 1983 |
|
| Action of vasodilating drugs on small and large arteries of hypertensive patients. | 1983 Jul-Aug |
|
| Mode of antihypertensive action of nitrendipine. | 1984 |
|
| [Liver lesions induced by dihydralazine and propranolol]. | 1985 |
|
| Comparative study on the short-term effects of angiotensin converting enzyme inhibitors (Lopirin, SQUIBB and Tensiomin), and dihydralazine in chronic cardiac failure. | 1988 |
|
| Additive effects of dihydralazine during enflurane or isoflurane hypotensive anaesthesia for spinal fusion. | 1988 May |
|
| Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. | 1996 Oct-Nov |
|
| [When hypertension becomes an emergency case: lower the blood pressure, but slowly!]. | 2003 May 29 |
|
| [Reversible loss of vision in severe preeclampsia: case report and review of the literature]. | 2003 Nov-Dec |
|
| The impact of maternal plasma volume expansion and antihypertensive treatment with intravenous dihydralazine on fetal and maternal hemodynamics during pre-eclampsia: a clinical, echo-Doppler and viscometric study. | 2004 Apr |
|
| [Determination of five components in compound hypotensive tablet by HPLC]. | 2004 Aug |
|
| Plasma volume and blood pressure regulation in hypertensive pregnancy. | 2004 Jul |
|
| Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity. | 2004 Mar |
|
| Flow injection chemiluminescence determination of dihydralazine sulphate based on permanganate oxidation sensitized by rhodamine B. | 2004 Nov-Dec |
|
| Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. | 2004 Oct |
|
| Flow-injection chemiluminescence determination of dihydralazine sulfate based on hexacyanoferrate(III) oxidation sensitized by eosin Y. | 2004 Oct 8 |
|
| Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. | 2004 Sep |
|
| 3,6-Bis(2-pyridyl)di-1,2,4-triazolo[3,4-a:4',3'-c]phthalazine. | 2004 Sep |
|
| Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. | 2004 Sep 21 |
|
| Hypertension in children with chronic renal failure. | 2005 |
|
| Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. | 2005 |
|
| Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. | 2005 Feb |
|
| Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia. | 2005 Jul |
|
| Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. | 2005 Mar |
|
| Evaluation of a strict protocol approach in managing women with severe disease due to hypertension in pregnancy: a before and after study. | 2005 Sep 30 |
|
| Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. | 2006 Aug |
|
| Changes in metabolism and blood flow following catecholamine stimulation in the synovial membrane measured with microdialysis. | 2006 Feb |
|
| Positive effects of nitric oxide on left ventricular function in humans. | 2006 Jul |
|
| [Hypertension in pregnancy]. | 2006 Mar |
|
| Dihydralazine treatment limits liver injury after hemorrhagic shock in rats. | 2006 Mar |
|
| Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? | 2007 Dec |
|
| Method development for dihydralazine with HPLC-MS/MS--an old but tricky substance in human plasma. | 2007 Jan 17 |
|
| Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. | 2007 Jun |
|
| Nitric oxide-deficiency regulates hepatic heme oxygenase-1. | 2008 Feb |
|
| Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery. | 2008 Jan |
|
| [Eclampsia at a teaching hospital in Ivory Coast: management, outcome and prognostic factors]. | 2008 Jul |
|
| Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. | 2008 Jul |
|
| Chemiluminescence investigation of carbon dioxide-enhanced oxidation of dihydralazine sulfate by peroxynitrite and its application to pharmaceutical analysis. | 2008 Jun 2 |
|
| Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. | 2009 |
|
| Effects of dihydralazine on renal water and aquaporin-2 excretion in humans. | 2009 |
|
| Emitting species in chemiluminescence reactions with acidic potassium permanganate: a re-evaluation based on new spectroscopic evidence. | 2009 Sep |
|
| Xenobiotic exposure and autoimmune hepatitis. | 2010 |
|
| Hemodynamic, morphometric and autonomic patterns in hypertensive rats - Renin-Angiotensin system modulation. | 2010 |
|
| [Drugs during preeclampsia. Fetal risks and pharmacology]. | 2010 Apr |
|
| Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system. | 2010 Jan |
|
| Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. | 2010 May |
|
| Autoimmune hepatitis triggered by nitrofurantoin: a case series. | 2010 Sep 23 |
|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: In mice bone marrow cells, dihydralazine induced a modest but statistically significant increase over controls in the frequency of sister chromatid exchanges, the rank of potencies being in this case dihydralazine greater than endralazine greater than hydralazine. In the Ames reversion test all three drugs behaved as direct-acting mutagens of low potency, whose activity was not influenced by rat liver nor by mouse liver or lung S-9 fractions. Hydralazine and dihydralazine elicited mixed genetic mechanisms of mutations, while endralazine exclusively induced frameshift errors in Salmonella DNA.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30220456
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
3RYP614N6L
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
71587248
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
70175-06-3
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY | |||
|
100000076099
Created by
admin on Fri Dec 15 18:37:20 GMT 2023 , Edited by admin on Fri Dec 15 18:37:20 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
